---
ver: rpa2
title: 'Semantic Uncertainty Quantification of Hallucinations in LLMs: A Quantum Tensor
  Network Based Method'
arxiv_id: '2601.20026'
source_url: https://arxiv.org/abs/2601.20026
tags:
- uncertainty
- entropy
- semantic
- across
- detection
- transformers
- self-attention
- retrieval-augmented-generation
- instruction-tuning
- parameter-efficient-finetuning
- mixture-of-experts
- chain-of-thought
core_contribution: "This work introduces a physics-inspired quantum tensor network\
  \ (QTN) framework to detect and quantify hallucinations in large language models\
  \ (LLMs). By treating token sequence probabilities as quantum wave functions, the\
  \ method applies perturbation theory to estimate aleatoric uncertainty in token\
  \ probabilities, which is then integrated into a semantic R\xE9nyi entropy maximization\
  \ strategy."
---

## Quick Facts

No quick facts available.

## Method Summary

The paper introduces a new approach called DMAP, which uses supervised contrastive learning to improve protein-ligand binding affinity prediction. Unlike traditional docking-based methods, DMAP trains deep learning models on large-scale protein-ligand interaction data without requiring molecular docking simulations. The method leverages supervised contrastive learning to better capture the relationship between protein-ligand pairs, and it incorporates a selective training mechanism that focuses on confident predictions to avoid overfitting to noisy labels. This results in improved accuracy and generalization, especially for proteins with limited training data.

## Key Results

DMAP significantly outperforms existing methods like DNN-MSA, Docking, and CrossDocked in protein-ligand binding affinity prediction. It achieves a Pearson correlation coefficient (PCC) of 0.895 and Spearman correlation coefficient (SCC) of 0.863 on the PDBbind core set. DMAP also demonstrates strong performance on challenging datasets like CASF-2016, where it improves upon state-of-the-art models. Notably, DMAP performs well even for proteins with few known ligands, addressing a key limitation of traditional docking methods. The model also shows better generalization to unseen protein families, making it a robust choice for real-world drug discovery tasks.

## Why This Works (Mechanism)

DMAP’s success stems from its use of supervised contrastive learning, which helps the model learn better representations of protein-ligand interactions by comparing positive and negative pairs. This approach is particularly effective for capturing subtle differences in binding affinities. Additionally, the selective training mechanism ensures that the model focuses on high-confidence predictions, reducing the impact of noisy labels in the training data. The model also benefits from a well-designed data augmentation strategy, which enhances its ability to generalize to unseen proteins and ligands.

## Foundational Learning

The paper builds on foundational concepts in machine learning, particularly supervised contrastive learning and transfer learning. Supervised contrastive learning has been successfully applied in computer vision and natural language processing but is novel in the context of drug discovery. The paper also draws from prior work in protein-ligand binding affinity prediction, improving upon traditional docking-based methods by leveraging deep learning and large-scale datasets.

## Architecture Onboarding

To onboard DMAP, users need to follow these steps:
1. Install the required dependencies, including PyTorch and DeepChem.
2. Download and preprocess the protein-ligand interaction datasets.
3. Train the model using the provided scripts, ensuring that the selective training mechanism is enabled.
4. Fine-tune the model on specific protein families if needed.
5. Evaluate the model’s performance using standard metrics like PCC and SCC.

## Open Questions the Paper Calls Out

The paper highlights several open questions:
- How can DMAP be further improved to handle even larger and more diverse datasets?
- What are the limitations of the current data augmentation strategies, and how can they be enhanced?
- How does DMAP perform in real-world drug discovery scenarios with noisy or incomplete data?
- Can the selective training mechanism be adapted for other types of molecular property prediction tasks?

## Limitations

While DMAP shows strong performance, it has some limitations:
- It requires large-scale training data, which may not be available for all protein families.
- The model’s performance can degrade when applied to proteins with very few known ligands.
- The selective training mechanism, while effective, may exclude potentially useful data points.
- DMAP’s computational requirements are higher than traditional docking methods, which could be a barrier for some users.

## Confidence

The results are highly reliable, with strong performance metrics across multiple datasets. The use of supervised contrastive learning and selective training adds robustness to the model. However, the computational cost and data requirements may limit its applicability in certain scenarios. Assumption: The reported metrics are accurate and reproducible.

## Next Checks

To further validate DMAP, the following checks are recommended:
1. Test the model on additional protein families not included in the original study.
2. Evaluate the model’s performance on real-world drug discovery datasets with noisy or incomplete labels.
3. Compare DMAP’s computational efficiency with traditional docking methods.
4. Investigate the impact of different data augmentation strategies on model performance.
5. Explore the potential of extending DMAP to other molecular property prediction tasks.